Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $325,520. This represents a 7.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $24,420.00.

Enliven Therapeutics Price Performance

ELVN traded down $0.21 on Tuesday, hitting $23.86. 192,813 shares of the stock were exchanged, compared to its average volume of 191,728. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The business has a 50-day moving average of $24.91 and a two-hundred day moving average of $24.37. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -12.56 and a beta of 1.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC raised its holdings in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after buying an additional 3,559 shares during the period. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the third quarter valued at $256,000. Verition Fund Management LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter worth about $271,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the 2nd quarter worth about $322,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ELVN shares. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and an average target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.